

Hansa Medical

- PRESS RELEASE -
July 12, 2018

Hansa Medical to Host Conference Call to Provide Second Quarter 2018 Business Update

On 19 July 2018, at 08:00AM CET, Hansa Medical will publish its Business Update for the second quarter of 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical's CEO and President, Søren Tulstrup, and the presentation will be held in English.

Slides used in the presentation will be live on the company's website during the call under Events & Webcast and will also be made available online after the call. To participate in the telephone conference, please use the dial in details shown below:

SE: +46856642665
UK: +442030089806
US: +18558315945

A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: <https://tv.streamfabriken.com/hansa-medical-q2-2018>

This is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below at 8:00 CET on July 12, 2018.

For further information, please contact:

Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46707175477
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com

About Hansa Medical

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, imlifidase (IdeS), is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin-cleaving enzymes are developed for repeat dosing with the objective of applying the Hansa Medical technology in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on Nasdaq Stockholm (ticker: HMED).